Kura Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kura Oncology (KURA).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

2S.Buy

12Buy

3Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$25Upside to Avg. PT+145.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$30
Aug 24, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$24
Aug 13, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$36→$38
Jul 28, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$36
Jun 15, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$24
Apr 14, 2026	Lake Street	Daniel Brims	Initiate	Buy	$23
Mar 24, 2026	Mizuho	Mara Goldstein	PT Cut	Outperform	$30→$25
Mar 13, 2026	UBS	David Dai	PT Cut	Buy	$16→$15
Mar 6, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$38→$36
Jan 13, 2026	Leerink Partners	—	PT Cut	Outperform	$25→$20
Jan 13, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$40
Nov 24, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$11→$28
Nov 14, 2025	UBS	David Dai	PT Raise	Buy	$14→$16
Nov 14, 2025	Wedbush	Robert Driscoll	PT Raise	Outperform	$36→$38
Oct 20, 2025	JMP Securities	Reni J. Benjamin	Maintained	Market Outperform	$24
Oct 20, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$40
Sep 30, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$40
Sep 4, 2025	Guggenheim	Brad Canino	Initiate	Neutral	—
Aug 11, 2025	JMP Securities	Reni J. Benjamin	PT Cut	Market Outperform	$28→$24
Jun 26, 2025	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—

More with Benzinga EdgeGet Access

Analyst Ratings News

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.

Avi Kapoor

PRO
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30

JP Morgan analyst Priyanka Grover initiates coverage on Kura Oncology (NASDAQ:KURA) with a Overweight rating and announces Price Target of $30.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38

Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $36 to $38.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.

Benzinga Newsdesk

Kura Oncology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Kura Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

PRO
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38

PRO
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

People Also Watch

People Also Watch

Kura Oncology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Kura Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROJP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30

PROCitizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

PROWedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38

PROWedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

PROCitizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

People Also Watch

People Also Watch

PRO
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

PRO
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38

PRO
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target